George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Have you though about getting a pet dog, Wyndrum?
Fair enough.
" AVA3996 has been selected as a candidate for preclinical development. Clinical Trial Authorisation (CTA) and/or Investigational New Drug (IND) filing expected H1 2023 and dosing of the first patient later in 2023."
The amount of RNS's that have contained statement that didn't materialise is ridiculous. Why is no one at Avacta accountable?
Interesting matml. All of this keeps bringing me back to why on earth did the CEO splash a whole heap of the bond fundraise on diagnostics businesses when the tx pipeline is well behind schedule?
I imagine there will be a bit of churn with some people flipping. Then its in everyone's interests for the SP to rise. Existing and new shareholders. The raise was significantly discounted as we all know. I'm expecting a decent rise into April and then with the P1 news at AACR this should anchor the share price.
This whole raise has been a shambles but worth reminding ourselves it was 20% dilution, so not huge.
It's up to Avacta now to manage some positive news flow.
You must be reading something I'm not. Dose expansions are part of a phase 1 trial.
From the 28 Feb RNS: "The dose expansions are expected to begin in H2 2024 in the USA, followed by the Phase 2 efficacy study, subject to funding and FDA approval, which the Board considers to be a major value-driving event for the Group. The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies."
Surely, the Company has to clarify this?
If indeed it is 1b trial why are they not calling it that? It is industry standard, no?
And 3396 should be dosed by then. Although they have been forecasting filing the Ind for God knows how long now. So I would t bet my house on it.
One would hope Avacta would be well into phase 2 and some positive noises are coming from the company by that point.
"We can see that from the 1b phase (now named as "leading up to P2") that's reappeared in the (nonsense) timelines from nowhere (thanks for the comms Al)."
I am glad someone else has noticed that. AS should be pushed to clarify this in the next Q & A. Why he isn't calling it phase 1b? Like the rest of the pharma world would in a clinical trial. Unless 1B isnt happening and he could clarify this as there is some confusion.
Careful Buena, you will be called a bee wetter for bringing that up.
Depends on the size of the eggs
More of a Rum man, Captain?
Correct Touk. Like Tiger bread isn't a Tiger.
There's big money in biscuits
Come on Alan! Let's get the shareprice back up.
At least! Come on Alan, lets get boosting.
Jeez, Ronny. Do you want the Euro millions numbers as well?.
In the turner pipe GANNT chart pretty sure it's due to finish by end of h1. But then sure I read they are still screening. So basically, dunno
This is worth a read with all the buzz around ADCs.
AVA6000 is a PDC
https://www.sciencedirect.com/science/article/abs/pii/S0223523423010863
My take is the Science for Pre|CISION is quite obvioisly brilliant so far. Maybe not As paradigm shifting but good enough to hopefully show even more efficacy in P2.
The issue with Avacta is operational. Comms borderline incomprehensible and plans constantly changing to the extent where you give up with timelines.
If Avacta can sort the operational side out, I am confident the market cap will rise significantly from here.